Products & Services · Finite-lived intangible assets, net
Generics — Finite-lived intangible assets, net
Viatris Generics — Finite-lived intangible assets, net decreased by 18.0% to $1.29B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 18.0%, from $1.57B to $1.29B.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2019
Last reportedQ4 2025
Rolls up toIntangibles (Net)
How to read this metric
A decrease typically reflects ongoing amortization, while a significant increase often follows strategic acquisitions of product portfolios or new intellectual property.
Detailed definition
This metric measures the net book value of identifiable intangible assets with finite useful lives, such as product righ...
Peer comparison
Comparable to 'Net Intangible Assets' or 'Product Rights' reported by other pharmaceutical companies with significant M&A activity.
Metric ID:
vtrs_segment_generics_finite_lived_intangible_assets_netHistorical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $4.71B | $3.99B | $2.11B | $1.57B | $1.29B |
| QoQ Change | — | -15.3% | -47.0% | -25.8% | -18.0% |
| YoY Change | — | -15.3% | -47.0% | -25.8% | -18.0% |
Range$1.29B – $4.71B
CAGR-72.7%
Avg YoY Growth-26.5%
Median YoY Growth-21.9%
Current Streak4+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's generics — finite-lived intangible assets, net?
- Viatris (VTRS) reported generics — finite-lived intangible assets, net of $1.29B in Q4 2025.
- How has Viatris's generics — finite-lived intangible assets, net changed year-over-year?
- Viatris's generics — finite-lived intangible assets, net decreased by 18.0% year-over-year, from $1.57B to $1.29B.
- What does generics — finite-lived intangible assets, net mean?
- The net accounting value of the company's owned product rights and patents that have a limited lifespan.